Cyclic Prosaposins Peptides and Uses Thereof - Cancer Treatment
Summary
USPTO published patent application US20260091083A1 filed by Children's Medical Center Corporation for cyclic prosaposin peptides used in cancer treatment and inflammatory diseases. The application (No. 19186486) was filed on April 22, 2025, and published April 2, 2026, naming Randolph S. Watnick as inventor.
What changed
USPTO published a patent application for cyclic prosaposin peptides and their therapeutic uses, specifically for cancer treatment and inflammatory diseases. The application (US20260091083A1) is assigned to Children's Medical Center Corporation with inventor Randolph S. Watnick. The peptides are classified under CPC codes A61K 38/12, A61K 38/08, and C07K 7/64.
This is a routine patent publication notification with no immediate compliance requirements. Pharmaceutical companies developing peptide-based cancer therapeutics should review the claims to assess potential overlap with their own IP portfolios. No deadlines or penalties are associated with this publication.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CYCLIC PROSAPOSIN PEPTIDES AND USES THEREOF
Application US20260091083A1 Kind: A1 Apr 02, 2026
Assignee
Children's Medical Center Corporation
Inventors
Randolph S. Watnick
Abstract
Provided herein are cyclic prosaposin peptides and compositions and uses thereof. Exemplary uses include use in the treatment of cancer or in the treatment of inflammatory diseases or disorders.
CPC Classifications
A61K 38/12 A61K 38/08 C07K 7/64
Filing Date
2025-04-22
Application No.
19186486
Named provisions
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Peptides (C07K) publishes new changes.